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demonstrated reverse remodeling as defined by a 10% reduction in the LV end systolic
volume (ESV). Patients with 10% reduction in LV ESV had significantly less 1 year
mortality (0% vs. 20%, p0.036) (Figure) and had: less diabetes, lower baseline LVEF,
higher LV ESV and LV end systolic diameter (ESD)posterior wall thickness (PWT), and
worst pulmonary vein flow with decreased pulmonary vein S/D velocity (all p0.05), less
post TAVR aortic insufficiency (AI) (p0.059), at 6 months of follow-up patients with
reverse remodeling were more likely to have more improvement in LV ESV, EDV, LVEF
and LV ESD (all p0.05) (Table). In the binary logistic regression analysis significant
predictors of reverse remodeling was the severity of AI after the procedure (OR 9.5, 95%
CI 1.3-68, p0.025).
Conclusions: Reverse LV remodeling is noticeable in a significant proportion of patients
after TAVR. It is associated with significant reduction in 1 year mortality after TAVR.
Severity of AI after the TAVR is a significant predictor of LV reverse remodeling after
TAVR.
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Background: As Medicare coverage policies around utilization of new aortic valve
technologies are beginning to include procedure utilization requirements for hospital
certification, it is increasingly important to know more about the geographic variation of
current aortic valve replacement (AVR) procedures. The purpose of this study is to
describe the variation in patterns of care and costs associated with AVR procedures in the
hospital inpatient setting from a Medicare perspective.
Methods: Medicare inpatient hospitalizations for aortic valve replacement (AVR)
procedures were identified using ICD-9-CM procedure codes found in the Medicare
Provider Analysis and Review (MEDPAR) 2010 database. Hospital volumes, charges,
costs, and reimbursements were summarized by hospital, Hospital Referral Region (HRR)
and Medicare region.
Results: We found a total of 48,449 inpatient AVR procedures completed across 1,147
Medicare participating hospitals in 2010. Total inpatient AVR procedure costs were $2.1
billion, with Medicare reimbursement totaling almost $2.4 billion. Per procedure, the
average hospital net Medicare margin was 10.3% or $5,927. The top 5 HRRs with the
highest volume of AVR procedures included Manhattan, NY, Los Angeles, CA,
Cleveland, OH, Boston, MA and Philadelphia, PA. Medicare Region 4 (Atlanta) and
Region 5 (Chicago) represented the highest regional volume of AVR procedures
capturing over 36% of market share with Region 8 (Denver) having the lowest AVR
procedure volume. Similarly, 36% of AVR procedures were performed at 9.4% of
hospitals.
Table 1- Top 5 Hospitals- Inpatient AVR Utilization and Costs
Hospital Name
Medicare
AVR
Procedure
Volume
Avg.
AVR
Hospital
Cost ($)
Avg. AVR
Hospital
Reimbursement
($)
Avg.
AVR
Hospital
Medicare
Net
Margin
($)
Avg.
AVR
Hospital
Medicare
Net
Margin
(%)
OH -
CLEVELAND -
CLEVELAND
CLINIC -
360180
928 $38,742 $51,093 $12,351 24.20%
NY - NEW
YORK - NEW
YORK-
PRESBYTERIAN
HOSPITAL -
330101
648 $51,437 $73,424 $21,986 29.90%
MN -
ROCHESTER -
MAYO CLINIC -
SAINT MARYS
HOSPITAL -
240010
503 $40,494 $50,629 $10,135 20.00%
NY - ROSLYN -
ST FRANCIS
HOSPITAL,
ROSLYN -
330182
413 $61,885 $50,735 -11150 -22.00%
MA - BOSTON -
BRIGHAM AND
WOMEN’S
HOSPTIAL -
220110
364 $55,486 $62,379 $6,893 11.10%
Conclusions: AVR procedures are seemingly concentrated in certain parts of the country
and at certain hospitals. As Medicare sets volume requirements to allow hospitals to
perform certain new AVR procedures, the implications of this variation warrant further
analysis.
TCT-898
Incidence and Impact of Acquired Thrombocytopenia on Bleeding Events and
Mortality after Transcatheter Aortic Valve Replacement (TAVR)
Philippe Genereux1, Susheel Kodali1, Martin Leon1, Philip Green1,
Benoit Daneault1, Jean-Michel Paradis1, Isaac George1, Ajay Kirtane1,
Rebecca Hahn1, Craig Smith1, Mathew Williams1
1Columbia University, New York, NY
Background: Transcatheter aortic valve replacement (TAVR) involves placement of a
stented valve across the native diseased aortic valve. Concern about platelets consumption
and acquired thrombocytopenia (AT) was raised in the early TAVR experience.
Methods: Between 2008 and 2011, 218 consecutive pts with severe aortic stenosis
underwent TAVR using the 23mm or 26mm Edwards SAPIEN valve. Platelet count was
evaluated the day prior and daily for 7 days after TAVR. AT was defined as a drop in
platelet count of50% of baseline. Thirty-day bleeding rate (life threatening or major by
VARC criteria) and 1-year mortality was evaluated.
Results: Post TAVR platelet count dropped by an average of 78	/44 x109/L.
Post-TAVR AT was present in 45/218 (20.6%) of subjects. At baseline, the AT group had
a higher frequency of female sex, prior coronary intervention, 23mm valve, higher mean
gradient and baseline platelet count. Post-op hemoglobin drop (3.3	/1.3 vs 2.3	/1.1,
p0.001) and at least 1 red blood cell transfusion (52.0% vs. 21.5%, p0.001) were more
frequent in AT group. Bleeding events occurred in 53.3% (24/45) in AT group vs 29.5%
(51/173) in no AT group [adjusted OR 3.3 95%CI [1.6-6.9], p0.002. One-year mortality
was higher in AT group [32.5% vs.18%, adjusted HR 3.2 (1.5-6.8) p0.002].
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